Drugs

Oxytocin Targets (2) Enzymes (1) Biointeractions (3)

IDENTIFICATION

Name Oxytocin

Accession Number DB00107 (BTD00016, BIOD00016)

Type Biotech

Groups Approved, Vet approved

Biologic Protein Based Therapies

Classification Hormones

Description Synthetic 9 residue cyclic peptide. The hormone is prepared synthetically to avoid possible
contamination with vasopressin (ADH) and other small polypeptides with biologic activity.

Protein structure

Protein chemical C43H66N12O12S2

formula

Protein average 1007.187 Da

weight

Sequences >DB00107 sequence

CYIQNCPLG

Download FASTA Format

Synonyms Oxitocina

Oxytocin

Prescription Products Show 10 entries Search

MARKETING MARKETING
NAME ↑↓ DOSAGE ↑↓ STRENGTH ↑↓ ROUTE ↑↓ LABELLER ↑↓ START ↑↓ END ↑↓ ↑↓ ↑↓

Oxytocin Injection, 10 Intravenous Cantrell Drug 2011-10-20 2012-11-09

solution [USP'U]/500mL Company

Oxytocin Injection, 10 [USP'U]/1mL Intramuscular; Cardinal Health 2000-08-10 2020-12-31

solution Intravenous

Oxytocin Injection, 10 Intravenous Cantrell Drug 2011-10-20 2012-11-12

solution [USP'U]/500mL Company

Oxytocin Injection, 20 Intravenous Cantrell Drug 2011-10-20 2017-12-06

L DATA AVAILABLE

solution [USP'U]/1000mL Company

Oxytocin Injection, 10 [USP'U]/1mL Intramuscular; Fresenius Kabi 2000-08-10 Not applicable

solution Intravenous USA, LLC

Oxytocin Injection, 20 Intravenous Cantrell Drug 2016-03-18 Not applicable

 solution [USP'U]/500mL Company

ADDITIONA
MARKETING MARKETING
Oxytocin
NAME ↑↓ Injection
DOSAGE ↑↓ 10 ↑↓
[USP'U]/1mL
STRENGTH ↑↓
Intramuscular;
ROUTE Hikma
LABELLER ↑↓ 1980-04-29
START ↑↓ ↑↓
Not applicable
END ↑↓ ↑↓
Intravenous Pharmaceuticals
USA Inc. Drugs
Oxytocin Injection, 30 Intravenous Cantrell Drug 2016-03-18 Not applicable
solution [USP'U]/1000mL Company

Oxytocin Injection 10 [USP'U]/1mL Intramuscular; Hikma 1980-04-29 Not applicable

Intravenous Pharmaceuticals
USA Inc.

Oxytocin Injection, 20 Intravenous Cantrell Drug 2011-10-20 2015-01-14

solution [USP'U]/1000mL Company

Showing 1 to 10 of 29 entries ‹ 1 2 3 ›

Generic Prescription Show 10 entries Search

Products
MARKETING MARKETING
NAME ↑↓ DOSAGE ↑↓ STRENGTH ↑↓ ROUTE ↑↓ LABELLER ↑↓ START ↑↓ END ↑↓ ↑↓ ↑↓

Oxytocin Injection 10 [iU]/1mL Intravenous Par 2012-06-01 2015-07-13

Pharmaceutical

Oxytocin Injection 100 Intramuscular; Hikma 2009-08-01 2014-10-01

[USP'U]/10mL Intravascular Farmaceutica

Oxytocin Injection 10 Intramuscular; Hikma 2009-08-01 2014-10-01

[USP'U]/1mL Intravenous Farmaceutica

ADDITIONAL DATA AVAILABLE

Oxytocin Injection 100 Intravenous Teva Parenteral 2008-01-24 2011-02-28
[USP'U]/10mL Medicines, Inc.

Oxytocin Injection 10 Intravenous Teva Parenteral 2008-01-24 2011-04-30

[USP'U]/1mL Medicines, Inc.

Oxytocin Injection 10 Intramuscular; West-Ward 2013-02-13 Not applicable

[USP'U]/1mL Intravenous Pharmaceuticals
Corp

Oxytocin Injection 10 Intramuscular; West-Ward 2013-02-13 Not applicable

[USP'U]/1mL Intravenous Pharmaceuticals
Corp

Oxytocin Injection, 10 Intramuscular; Sagent 2018-04-01 2018-07-19

solution [USP'U]/1mL Intravenous Pharmaceuticals

Oxytocin Injection 10 [iU]/1mL Intravenous Par 2012-06-01 2015-04-30

Pharmaceutical

Showing 1 to 9 of 9 entries ‹ 1 ›

Mixture Products Show 10 entries Search

MARKETING MARKETING
NAME ↑↓ INGREDIENTS DOSAGE ↑↓ ROUTE ↑↓ LABELLER ↑↓ START ↑↓ END ↑↓ ↑↓ ↑↓

Bakumokon Oxytocin (0.01 Liquid Topical DS 2015-02-09 2017-10-19

5% Minoxidil mg/100mg) + LABORATORIES,
Dutasteride (0.1 INC.
mg/100mg) +
Minoxidil (5
mg/100mg)

Bakumokon Oxytocin (0.01 Liquid Topical DS 2015-02-09 2017-10-11

7% Minoxidil mg/100mg) + LABORATORIES,
Sulfate Dutasteride (0.1 INC.
mg/100mg) +
Minoxidil sulfate (7
mg/100mg)

Showing 1 to 2 of 2 entries ‹ 1 ›

Unapproved/Other Show 10 entries Search

Products
 MARKETING MARKETING
NAME ↑↓ INGREDIENTS DOSAGE ↑↓ ROUTE ↑↓ LABELLER ↑↓ START ↑↓ END ↑↓ ↑↓ ↑↓

Oxytocin Oxytocin (30 Injection, Intravenous Cantrell Drug 2011-10-20 Not applicable
[USP'U]/500mL) solution Company Drugs

Oxytocin Oxytocin (2 Injection, Intravenous Cantrell Drug 2012-11-12 Not applicable

[USP'U]/100mL) solution Company

Oxytocin Oxytocin (10 Injection, Intravenous Cantrell Drug 2012-07-30 Not applicable
[USP'U]/1000mL) solution Company

Oxytocin Oxytocin (10 Injection, Intravenous Cantrell Drug 2011-10-20 2012-11-09

[USP'U]/500mL) solution Company

Oxytocin Oxytocin (10 Injection, Intravenous Cantrell Drug 2011-10-20 2012-11-12

[USP'U]/500mL) solution Company

Oxytocin Oxytocin (2 Injection, Intravenous Cantrell Drug 2011-10-20 Not applicable

[USP'U]/100mL) solution Company

Oxytocin Oxytocin (20 Injection, Intravenous Cantrell Drug 2011-10-20 2017-12-06

[USP'U]/1000mL) solution Company

Oxytocin Oxytocin (20 Injection, Intravenous Cantrell Drug 2016-03-18 Not applicable
[USP'U]/500mL) solution Company

Oxytocin Oxytocin (30 Injection, Intravenous Cantrell Drug 2016-03-18 Not applicable
[USP'U]/1000mL) solution Company

Oxytocin Oxytocin (20 Injection, Intravenous Cantrell Drug 2011-10-20 2015-01-14

[USP'U]/1000mL) solution Company

Showing 1 to 10 of 13 entries ‹ 1 2 ›

Categories Amino Acids, Peptides, and Oxytocin and Analogues Pituitary Hormones, Posterior
Proteins
Oxytocin, analogs & derivatives Posterior Pituitary Lobe Hormones
Genito Urinary System and Sex
Oxytocin, antagonists & inhibitors Potential QTc-Prolonging Agents
Hormones
Peptide Hormones QTc Prolonging Agents
Hormones
Peptides Reproductive Control Agents
Hormones, Hormone Substitutes,
and Hormone Antagonists Pituitary and Hypothalamic Systemic Hormonal Preparations,
Hormones and Analogues Excl. Sex Hormones and Insulins
Increased Uterine Smooth Muscle
Contraction or Tone Pituitary Hormones Uterotonic agents

UNII 1JQS135EYN

CAS number 50-56-6

PHARMACOLOGY

Indication Used for labor induction, augmentation of labor, postpartum abbreviation of third stage of labor,
postpartum control of uterine bleeding, termination of pregnancy and for the evaluation of fetal
respiratory capability. Oxytocin cannot be used for elective induction of labor, there must be a
clear medical requirement.

Associated Abortion induced incomplete

Conditions
Inevitable abortion

Postpartum Bleeding

Associated Therapies Induction of Uterine contractions

Reinforcement of labor

Pharmacodynamics Indirectly stimulates contraction of uterine smooth muscle by increasing the sodium permeability
of uterine myofibrils. Increases contraction amplitude and frequency, which tends to decrease
cervical activity, produce dilation and effacement of the cervix, and transiently impede uterine
 blood flow; contractions produced by oxytocin at term are similar to those occurring during
spontaneous labor. High estrogen concentrations lower the threshold for uterine response to
oxytocin. Uterine response increases with the duration of pregnancy and is greater in labor than
DrugsContracts
when not in labor; only very large doses elicit contractions in early pregnancy.
myoepithelial cells surrounding the alveoli of the breasts, forcing milk from the alveoli into the
larger ducts and facilitating milk ejection. Minimal antidiuretic activity relative to vasopressin;
water intoxication possible at high doses and/or excessive electrolyte-free fluid.

Mechanism of action Uterine motility depends on the formation of the contractile protein actomyosin under the
influence of the Ca2+-dependent phosphorylating enzyme myosin light-chain kinase. Oxytocin
promotes contractions by increasing the intracellular Ca2+, which in turn activates myosin's light
chain kinase.. Oxytocin has specific receptors in the muscle lining of the uterus and the receptor
concentration increases greatly during pregnancy, reaching a maximum in early labor at term.

TARGET ACTIONS ORGANISM

A Oxytocin receptor agonist Humans

U Oxytocin-neurophysin 1 binder Humans

ADDITIONAL DATA AVAILABLE ADDITIONAL DATA AVAILABLE ADDITIONAL DATA AVAILABLE

Adverse Effects Contraindications Blackbox Warnings

Comprehensive structured data on known drug
adverse effects with statistical prevalence.
MedDRA and ICD10 ids are provided for adverse
effect conditions and symptoms.
LEARN MORE
Structured data covering drug
contraindications. Each contraindication
describes a scenario in which the drug is not to
be used. Includes restrictions on co-
administration, contraindicated populations,
and more.
Structured data representing warnings from the
black box section of drug labels. These warnings
cover important and dangerous risks,
contraindications, or adverse effects.
LEARN MORE

LEARN MORE

Absorption Uterine response a er IV administration is immediate and subsides a er 1 hour. Uterine

contractions occur 3-5mins a er IM administration and decreases within 2-3 hours. When 100-
200milliunits is administered IV, contractions of the myoepithelial tissue surrounding the alveoli
of the breasts occur within minutes and last for about 20 mins.

Volume of Distributes throughout the extracellular fluid and crosses the placenta. It is probable that it also
distribution distributes into milk in small amounts.

Protein binding 30%

Metabolism
Oxytocin is rapidly metabolized in the liver and also in the plasma by oxytocinases. It is also
metabolized to a smaller degree by the mammary glands.

Route of elimination Biliary and renal (excreted unchanged in the urine)

Half life 1-6 min, this is decreased in late pregnancy and during lactation.

Clearance Not Available

Toxicity Oxytocin can produce a severe water intoxication due to its antidiuretic effect. Prolonged IV
infusions of more 40milliunits/min are usually the cause. Severe water intoxication with
convulsions, coma, and death can occur. Some neonatal seizures have also been reported.
Consider potential for water intoxication, particularly when administered by IV infusion and
patient is receiving oral fluids. Uterine effects: High doses or hypersensitivity to oxytocin may
cause uterine hypertonicity, spasm, tetanic contraction, or rupture of the uterus. There have also
been reported allergic and anaphylactic reactions to oxytocin but they were rarely fatal.

Affected organisms Humans and other mammals

Pathways Not Available

 Pathways Not Available

Pharmacogenomic Not Available

Effects/ADRs Drugs

INTERACTIONS

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are
experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does
not necessarily mean no interactions exist.

ALL DRUGS APPROVED VET APPROVED NUTRACEUTICAL ILLICIT WITHDRAWN

INVESTIGATIONAL EXPERIMENTAL

Show 10 entries Search

DRUG ↑↓ INTERACTION ↑↓
Abexinostat The risk or severity of QTc prolongation can be increased when Oxytocin is combined with
Abexinostat.

Acebutolol The risk or severity of QTc prolongation can be increased when Oxytocin is combined with
Acebutolol.

Aceprometazine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with
Aceprometazine.

ADDITIONAL DATA AVAILABLE

Acetyldigoxin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with
Acetyldigoxin.

Acrivastine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with
Acrivastine.

Adenosine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with
Adenosine.

Ajmaline The risk or severity of QTc prolongation can be increased when Oxytocin is combined with
Ajmaline.

Alfuzosin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with
Alfuzosin.

Alimemazine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with
Alimemazine.

Amantadine The risk or severity of QTc prolongation can be increased when Oxytocin is combined with
Amantadine.

Showing 1 to 10 of 363 entries ‹ 1 2 3 4 5 … 37 ›

Food Interactions Not Available

REFERENCES

Synthesis Reference Kerstin Uvnas-Moberg, Thomas Lundeberg, "Use of substances having oxytocin activity for
preparation of medicaments for wound healing." U.S. Patent US6262021, issued August, 1988.
US6262021

General References
1. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E: Oxytocin increases trust in humans. Nature. 2005 Jun 2;435(7042):673-6.
[PubMed:15931222]
2. Takayanagi Y, Yoshida M, Bielsky IF, Ross HE, Kawamata M, Onaka T, Yanagisawa T, Kimura T, Matzuk MM, Young LJ, Nishimori
K: Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. Proc Natl Acad Sci U S A. 2005 Nov
1;102(44):16096-101. Epub 2005 Oct 25. [PubMed:16249339]
3. Carmichael MS, Humbert R, Dixen J, Palmisano G, Greenleaf W, Davidson JM: Plasma oxytocin increases in the human sexual
response. J Clin Endocrinol Metab. 1987 Jan;64(1):27-31. [PubMed:3782434]
4. Paquin J, Danalache BA, Jankowski M, McCann SM, Gutkowska J: Oxytocin induces differentiation of P19 embryonic stem
cells to cardiomyocytes. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9550-5. Epub 2002 Jul 1. [PubMed:12093924]
5. Jankowski M, Danalache B, Wang D, Bhat P, Hajjar F, Marcinkiewicz M, Paquin J, McCann SM, Gutkowska J: Oxytocin in cardiac
ontogeny. Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13074-9. Epub 2004 Aug 17. [PubMed:15316117]
 External Links KEGG Drug D00089

KEGG Compound C00746 Drugs

PubChem Substance 46506775

RxNav 7824

ChEMBL CHEMBL395429

Therapeutic Targets Database DAP001156

PharmGKB PA450760

Guide to Pharmacology GtP Drug Page

RxList RxList Drug Page

Drugs.com Drugs.com Drug Page

Wikipedia Oxytocin

ATC Codes G02AC01 — Methylergometrine and oxytocin

G02AC — Ergot alkaloids and oxytocin incl. analogues, in combination
G02A — UTEROTONICS
G02 — OTHER GYNECOLOGICALS
G — GENITO URINARY SYSTEM AND SEX HORMONES

H01BB02 — Oxytocin
H01BB — Oxytocin and analogues
H01B — POSTERIOR PITUITARY LOBE HORMONES
H01 — PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

AHFS Codes 76:00.00 — Oxytocics

CLINICAL TRIALS

Clinical Trials Show 10 entries Search

PHASE ↑↓ STATUS ↑↓ PURPOSE ↑↓ CONDITIONS ↑↓ COUNT ↑↓

0 Completed Basic Expressed Emotion / Social Cognition 1
Science

0 Completed Basic Facial Expressions 1

Science

0 Completed Basic Healthy Volunteers 6

Science

0 Completed Basic Psychology, Social 3

Science

0 Completed Basic Social Activity 1

Science

0 Completed Basic Social Perception 1

Science

0 Completed Other Eating Behavior 1

0 Completed Other Overweight and Obesity 1

0 Completed Prevention Healthy Volunteers 1

0 Completed Treatment Alcohol Dependence / Post Traumatic Stress Disorder (PTSD) 1

Showing 1 to 10 of 384 entries ‹ 1 2 3 4 5 … 39 ›

PHARMACOECONOMICS

Manufacturers App pharmaceuticals llc Baxter healthcare corp Teva parenteral medicines
anesthesia critical care inc
 anesthesia critical care inc

Abbott laboratories Jhp pharmaceuticals llc Novartis pharmaceuticals

pharmaceutical products corp
div Drugs

Packagers APP Pharmaceuticals BAM Biotech Baxter International Inc. Bimeda Inc.

Cardinal Health Gland Pharma Ltd. MWI Veterinary Supply Co. Pharmedium

Central Admixture Hikma Pharmaceuticals Osburn Drug Co. Teva Pharmaceutical

Pharmacy Services Industries Ltd.
JHP Pharmaceuticals LLC PD-Rx Pharmaceuticals Inc.
Gallipot Vedco Inc.
Monarch Pharmacy Pharmakon
Watson Pharmaceuticals

Dosage forms Show 10 entries Search

FORM ↑↓ ROUTE ↑↓ STRENGTH ↑↓

Liquid Topical

Injection Intramuscular; Intravascular 100 [USP'U]/10mL

Injection Intravenous 10 [iU]/1mL

Injection Intravenous 10 [USP'U]/1mL

Injection Intravenous 100 [USP'U]/10mL

Injection, solution Intramuscular; Intravenous 10 [USP'U]/1mL

Injection, solution Intravenous 10 [USP'U]/500mL

Injection, solution Intravenous 10 [USP'U]/1000mL

Injection, solution Intravenous 2 [USP'U]/100mL

Injection, solution Intravenous 20 [USP'U]/500mL

Showing 1 to 10 of 18 entries ‹ 1 2 ›

Prices Show 10 entries Search

UNIT DESCRIPTION ↑↓ COST ↑↓ UNIT ↑↓

Oxytocin powder 1762.25USD g

Oxytocin 10 unit/ml vial 9.84USD vial

Pitocin 10 unit/ml vial 1.6USD ml

Oxytocin-lr 40 unit/500 ml 0.09USD ml

Oxytocin-d5w-lr 40 unit/500 ml 0.07USD ml

Oxytocin-d5lr 30 unit/500 ml 0.06USD ml

Oxytocin-lr 20 unit/500 ml 0.06USD ml

Oxytocin-d5w-lr 15 unit/500 ml 0.05USD ml

Oxytocin-d5w-lr 20 unit/500 ml 0.05USD ml

Oxytocin-lr 10 unit/500 ml 0.05USD ml

Showing 1 to 10 of 26 entries ‹ 1 2 3 ›

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents Not Available

PROPERTIES

State Liquid

Experimental PROPERTY VALUE SOURCE

Properties
hydrophobicity -2.7 Not Available
 y p y
PROPERTY
isoelectric point VALUE
5.51 SOURCE
Not Available

TAXONOMY Drugs

Description Not Available

Kingdom Organic Compounds

Super Class Organic Acids

Class Carboxylic Acids and Derivatives

Sub Class Amino Acids, Peptides, and Analogues

Direct Parent Peptides

Alternative Parents Not Available

Substituents Not Available

Molecular Framework Not Available

External Descriptors Not Available

TARGETS

1. Oxytocin receptor Binding Properties Details

Kind Protein

Organism Humans

Pharmacological action Yes

Actions Agonist
General Function Vasopressin receptor activity

Specific Function Receptor for oxytocin. The activity of this receptor is mediated by G
proteins which activate a phosphatidylinositol-calcium second messenger
system.

Gene Name OXTR

Uniprot ID P30559

Uniprot Name Oxytocin receptor

Molecular Weight 42770.99 Da

References

1. Spyranti Z, Fragiadaki M, Magafa V, Borovickova L, Spyroulias GA, Cordopatis P, Slaninova J: In position 7 L- and D-Tic-substituted oxytocin and
deamino oxytocin: NMR study and conformational insights. Amino Acids. 2010 Jul;39(2):539-48. doi: 10.1007/s00726-009-0470-1. Epub 2010 Jan
27. [PubMed:20108008]
2. Frantz MC, Rodrigo J, Boudier L, Durroux T, Mouillac B, Hibert M: Subtlety of the structure-affinity and structure-efficacy relationships around a
nonpeptide oxytocin receptor agonist. J Med Chem. 2010 Feb 25;53(4):1546-62. doi: 10.1021/jm901084f. [PubMed:20104850]
3. Gimpl G, Reitz J, Brauer S, Trossen C: Oxytocin receptors: ligand binding, signalling and cholesterol dependence. Prog Brain Res. 2008;170:193-
204. doi: 10.1016/S0079-6123(08)00417-2. [PubMed:18655883]
4. Ahn TG, Han SJ, Cho YS, An TH, Pak SC, Flouret G: In vivo activity of the potent oxytocin antagonist on uterine activity in the rat. In Vivo. 2004
Nov-Dec;18(6):763-6. [PubMed:15646817]
5. Furman DJ, Chen MC, Gotlib IH: Variant in oxytocin receptor gene is associated with amygdala volume. Psychoneuroendocrinology. 2011
Jul;36(6):891-7. doi: 10.1016/j.psyneuen.2010.12.004. Epub 2011 Jan 3. [PubMed:21208749]
 2. Oxytocin-neurophysin 1 Details

Drugs
Kind Protein

Organism Humans

Pharmacological action Unknown

Actions Binder

General Function Not Available

Specific Function Neurophysin 1 specifically binds oxytocin.Oxytocin causes contraction of

the smooth muscle of the uterus and of the mammary gland.

Gene Name OXT

Uniprot ID P01178

Uniprot Name Oxytocin-neurophysin 1

Molecular Weight 12721.51 Da

References

1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
[PubMed:17016423]
2. Land H, Grez M, Ruppert S, Schmale H, Rehbein M, Richter D, Schutz G: Deduced amino acid sequence from the bovine oxytocin-neurophysin I
precursor cDNA. Nature. 1983 Mar 24-30;302(5906):342-4. [PubMed:6687626]
3. Rao VV, Loffler C, Battey J, Hansmann I: The human gene for oxytocin-neurophysin I (OXT) is physically mapped to chromosome 20p13 by in situ
hybridization. Cytogenet Cell Genet. 1992;61(4):271-3. [PubMed:1486803]

ENZYMES

1. Prolyl endopeptidase Details

Kind Protein

Organism Humans

Pharmacological action Unknown

Actions Substrate

General Function Serine-type peptidase activity

Specific Function Cleaves peptide bonds on the C-terminal side of prolyl residues within
peptides that are up to approximately 30 amino acids long.

Gene Name PREP

Uniprot ID P48147

Uniprot Name Prolyl endopeptidase

Molecular Weight 80698.945 Da

References

1. Irazusta J, Silveira PF, Gil J, Varona A, Casis L: Effects of hydrosaline treatments on prolyl endopeptidase activity in rat tissues. Regul Pept. 2001
Sep 15;101(1-3):141-7. [PubMed:11495689]
2. Bausback HH, Ward PE: Vascular, post proline cleaving enzyme: metabolism of vasoactive peptides. Adv Exp Med Biol. 1986;198 Pt A:397-404.
[PubMed:3544718]
3. Yoshimoto T, Nishimura T, Kita T, Tsuru D: Post-proline cleaving enzyme (prolyl endopeptidase) from bovine brain. J Biochem. 1983
Oct;94(4):1179-90. [PubMed:6361010]
Drug created on June 13, 2005 07:24 / Updated on July 03, 2020 08:33

Drugs

About Support Commercial Data

About DrugBank.ca Help Center Clinical Drug Data

Blog DrugBank.ca FAQs This project is supported Canadian

by theDrug
Scientific DataInstitutes of Health Research
(award #111062), Alberta Innovates - Health Solutions, and by The
Wishart Research Group Contact Support Contact Sales
Metabolomics Innovation Centre (TMIC), a nationally-funded research and
Careers core facility that supports a wide range of cutting-edge metabolomic studies.
TMIC is funded by Genome Alberta, Genome British Columbia, and Genome
Terms of Use Canada, a not-for-profit organization that is leading Canada's national
Privacy Policy genomics strategy with funding from the federal government. Maintenance,
support, and commercial licensing is provided by OMx Personal Health
Analytics, Inc. Designed by Educe Design & Innovation Inc.